<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04790968</url>
  </required_header>
  <id_info>
    <org_study_id>REK 50719</org_study_id>
    <nct_id>NCT04790968</nct_id>
  </id_info>
  <brief_title>Combined PSMA PET/MRI for Detection of Lymph Node Metastases in High-risk Prostate Cancer Patients</brief_title>
  <official_title>Combined PSMA PET/MRI for Detection of Lymph Node Metastases in High-risk Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For high-risk prostate cancer patients, detection of lymph node metastases is crucial to&#xD;
      ensure optimal treatment.&#xD;
&#xD;
      Standard treatment for these patients is radiotherapy or surgery. The surgery involves&#xD;
      resection of the prostate and the pelvic lymph nodes. Currently, the most reliable method to&#xD;
      confirm lymph node metastases is by histologic examination of the resected lymph nodes.&#xD;
      Ideally, one should be able to detect lymph node metastases prior to treatment. Then, the&#xD;
      treatment could be better adjusted to each patient.&#xD;
&#xD;
      Imaging methods such as prostate specific membrane antigen positron emission tomography&#xD;
      (PSMA-PET) can possibly aid the detection of lymph node metastases. In this study, the&#xD;
      investigators want to test whether PSMA-PET or a combination of PSMA-PET and MRI (magnetic&#xD;
      resonance imaging) can improve staging of lymph nodes before treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High-risk prostate cancer patients have a high probability for lymph node metastases in the&#xD;
      pelvic region. The lymph node status is an important prognostic factor in determining the&#xD;
      risk of later relapses and a factor in treatment planning. Lymph node metastases outside the&#xD;
      pelvis usually signify systemic treatment not amendable for curative treatment.&#xD;
&#xD;
      High-risk prostate cancer patients are treated by radiotherapy or surgical resection of the&#xD;
      prostate and the pelvic lymph nodes. Currently, the most reliable method for confirming lymph&#xD;
      node metastases is by bilateral pelvic lymph node dissection during surgical treatment, and&#xD;
      subsequent histologic examination. However, todays state-of-the art methods for the detection&#xD;
      of lymph node metastases prior to treatment are clearly inadequate. Detection of lymph node&#xD;
      metastases is crucial for determining whether the patient (i) is a candidate for localized&#xD;
      treatment and, if so, (ii) optimizing the extent of the lymph node dissection / radiation&#xD;
      field for localized treatment. Non-standard imaging methods such as prostate specific&#xD;
      membrane antigen (PSMA)-PET-imaging have been shown to be able to aid in the detection of&#xD;
      lymph node metastases. The purpose of this study is to test whether PSMA-PET or a combination&#xD;
      of PSMA-PET and MRI can improve the sensitivity and specificity for pre-treatment lymph node&#xD;
      staging in order to reduce both over- and undertreatment of high-risk prostate cancer&#xD;
      patients.&#xD;
&#xD;
      In this multi-centre study, at least 80 patients with high-grade prostate cancer (ISUP grade&#xD;
      group 4 or higher) will be examined with PSMA PET/MRI and PET/CT. Of these 80 patients, 60&#xD;
      will be men who are scheduled for radical prostatectomy with extended pelvic lymph node&#xD;
      dissection (ePLND) (surgery cohort) and 20 will be men who are scheduled for radiation&#xD;
      treatment to the prostate and pelvic lymph nodes (radiotherapy cohort). After the PET&#xD;
      examinations, all patients will receive standard treatment and follow-up, which is determined&#xD;
      by national guidelines and the patient's treating urologist and/or oncologist. Imaging data&#xD;
      will be analyzed by radiologists and nuclear medicine physicians in collaboration. The&#xD;
      imaging findings in the surgery cohort will be compared to the histology outcome after ePLND&#xD;
      to assess the sensitivity and specificity for detection of lymph node involvement with PSMA&#xD;
      PET/MRI. The data from the radiotherapy cohort will be used to assess the feasibility of PSMA&#xD;
      PET/MRI-based radiotherapy planning. Advanced image processing and analysis methodology&#xD;
      including the use of artificial intelligence will also be applied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy of PSMA PET and combined PSMA PET/MRI</measure>
    <time_frame>1 month</time_frame>
    <description>To compare the diagnostic accuracy of PSMA PET and combined PSMA PET/MRI to that of the current standard multiparametric MRI, using histopathology as the gold standard.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of PSMA PET/MRI</measure>
    <time_frame>1 month</time_frame>
    <description>To evaluate the sensitivity and specificity of PSMA PET/MRI to detect positive lymph nodes in high-risk prostate cancer patients in a prospective, multicenter study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of PSMA PET/MRI versus PET/CT</measure>
    <time_frame>1 month</time_frame>
    <description>Compare the performance of PET/MRI to PET/CT for detection of lymph node metastases</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>PSMA-PET/MRI and PET/CT for detection of lymph node metastases.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patients will undergo an MRI-, PET/MRI- and PET/CT-examination (on the same day) prior to treatment.&#xD;
Patients in the radiotherapy cohort will additionally undergo an MRI examination after hormonal treatment, before radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PSMA-PET</intervention_name>
    <description>Prostate specific membrane antigen positron emission tomography</description>
    <arm_group_label>PSMA-PET/MRI and PET/CT for detection of lymph node metastases.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PSMA-PET/MRI</intervention_name>
    <description>Prostate specific membrane antigen positron emission tomography combined with magnetic resonance imaging</description>
    <arm_group_label>PSMA-PET/MRI and PET/CT for detection of lymph node metastases.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PSMA-PET/CT</intervention_name>
    <description>Prostate specific membrane antigen positron emission tomography combined with computed tomography imaging</description>
    <arm_group_label>PSMA-PET/MRI and PET/CT for detection of lymph node metastases.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria (surgery cohort):&#xD;
&#xD;
          -  High risk localized/locally advanced prostate cancer patients who are candidates for&#xD;
             radical prostatectomy plus bilateral extended PLND; ISUP Gleason grade group ≥ 4&#xD;
&#xD;
        Inclusion criteria (radiotherapy cohort):&#xD;
&#xD;
          -  High-risk localized/locally advanced prostate cancer patients scheduled for radiation&#xD;
             treatment of the prostate and pelvic lymph nodes; ISUP Gleason grade group ≥ 4&#xD;
&#xD;
        Exclusion criteria (surgery and radiotherapy cohort):&#xD;
&#xD;
          -  Prior history of any other cancer the last 5 years excluding basal cell carcinoma&#xD;
&#xD;
          -  Proven metastases in bones or other distant metastases&#xD;
&#xD;
          -  General contra-indications for MRI (pacemaker, aneurysm clips, any form of metal in&#xD;
             the body, severe claustrophobia)&#xD;
&#xD;
          -  Serious concomitant systemic disorders that in the opinion of the investigator would&#xD;
             compromise the patient's ability to complete the study or interfere with the&#xD;
             evaluation of the efficacy and safety of the study objectives&#xD;
&#xD;
          -  Metal implants in the pelvic region which will deteriorate PET/MR/CT image quality.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Øystein Risa, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Norwegian University of Science and Technology, NTNU</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Morten Troøyen, MD</last_name>
    <role>Study Director</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tone Frost Bathen, prof</last_name>
    <phone>95021097</phone>
    <phone_ext>0047</phone_ext>
    <email>tone.bathen@ntnu.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ingerid Skjei Knudtsen, PhD</last_name>
    <phone>47393211</phone>
    <phone_ext>0047</phone_ext>
    <email>ingerid.s.knudtsen@ntnu.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alfred Honoré, MD, PhD</last_name>
      <phone>94282796</phone>
      <phone_ext>0047</phone_ext>
      <email>alfred.honore@helse-bergen.no</email>
    </contact>
    <contact_backup>
      <last_name>Kristina Førde</last_name>
      <phone>55974723</phone>
      <phone_ext>0047</phone_ext>
      <email>kristina.forde@helse-bergen.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hosptial of North Norway</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hege S Haugnes, MD, PhD</last_name>
      <phone>99277080</phone>
      <phone_ext>0047</phone_ext>
      <email>hege.sagstuen.haugnes@unn.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital, Trondheim University Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torgrim Tandstad, MD, PhD</last_name>
      <phone>72826166</phone>
      <phone_ext>0047</phone_ext>
      <email>torgrim.tandstad@stolav.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diagnostic imaging</keyword>
  <keyword>Positron-emission tomography</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Prostate-specific antigen</keyword>
  <keyword>Lymph Nodes</keyword>
  <keyword>PSMA</keyword>
  <keyword>PET</keyword>
  <keyword>Molecular imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

